About this trial
This study is a necessary and important step in the development of a new therapy for upper limb functional recovery in patients with severe motor impairment. It is the first clinical trial of non-invasive brain stimulation (repetitive transcranial magnetic stimulation or rTMS) delivered to excite the undamaged hemisphere (specifically the contralesional higher motor cortices or cHMC) in stroke. Therefore, this study will determine whether the positive results obtained in our short-term pilot study can be made to last longer and produce functional benefits in severe patients with the application of brain stimulation in combination with long-term rehabilitation therapy. Rehabilitation therapy administered is called contralaterally controlled functional electrical stimulation (CCFES). Determining whether combining rTMS facilitating the cHMC with CCFES produces synergistic gains in functional abilities in severe patients is necessary for acceptance by the clinical community and to move this technology toward commercialization and widespread dissemination. The proposed study will determine whether the combination of rTMS facilitating the cHMC with CCFES produces greater improvements in upper extremity function in severe participants who are ≥6 months from stroke onset than the combination of rTMS facilitating the damaged hemisphere (specifically the ipsilesional primary motor cortex, iM1) and CCFES or the combination of sham rTMS and CCFES. The secondary purposes are to define which patients benefit most from the treatments, which may inform future device and treatment development and clinical translation, and to explore what distinct effects the three treatments have on the brain. To accomplish these purposes, we are conducting a clinical trial that enrolls severe stroke patients.
Eligibility criteria
Qualifiers
age 18 to 90 years old at time of randomization
greater than 6 months since a first clinical cortical or subcortical, ischemic or hemorrhagic stroke
severe upper limb hemiparesis defined as less than 10° active wrist extension or less than 10° active thumb abduction/extension or less than 10° active extension in at least two additional digits (i.e., will not meet minimum CIMT criteria)
ability to follow 3-stage commands and can remember 2 items from a list of 3 items after 3 minutes
Disqualifiers
metal implant in the head
history of seizures as an adult
history of alcohol or substance abuse less than 10yrs prior to enrollment
intake of anticonvulsants or anti-depressants contraindicated with TMS
Trial design
Treatments tested in this trial
- Contralaterally Controlled Functional Electrical Stimulation
- New rTMS approach
- Conventional rTMS approach
- Sham rTMS approach
Treatment groups
Sponsors and collaborators
The Cleveland Clinic
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator